Kinimmune is a clinical-stage pharmaceutical company developing intratumoral immunostimulants for unlocking the full potential of checkpoint inhibition in solid tumors. Precision drug delivery for tuning the immune system. Kinimmune is discovering and developing quick-to-market intratumoral immunotherapies for maximized safety and efficacy in solid tumors. Our immunotherapy products address unmet medical needs by applying our technologies to parent drugs with clinical proof-of-concept or clinically validated pathways. This strategy stands to benefit cancer patients by enabling new therapeutic interventions with proven track records and minimalized safety burdens. With extensive team experience in biotechnology and immunotherapy, we’re working to harness the immune system's potential to fight cancer.